These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 15583075)

  • 21. Leptin and the central neural mechanisms of obesity hypertension.
    Rahmouni K; G Haynes W
    Drugs Today (Barc); 2002 Dec; 38(12):807-17. PubMed ID: 12582470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leptin modulates orexigenic effects of ghrelin and attenuates adiponectin and insulin levels and selectively the dark-phase feeding as revealed by central leptin gene therapy.
    Ueno N; Dube MG; Inui A; Kalra PS; Kalra SP
    Endocrinology; 2004 Sep; 145(9):4176-84. PubMed ID: 15155574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is microvascular flow rate related to ghrelin, leptin and adiponectin levels?
    Tigno XT; Selaru IK; Angeloni SV; Hansen BC
    Clin Hemorheol Microcirc; 2003; 29(3-4):409-16. PubMed ID: 14724368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leptin and cardiovascular diseases.
    Luo JD; Zhang GS; Chen MS
    Drug News Perspect; 2005 Sep; 18(7):427-31. PubMed ID: 16362081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. To eat or not to eat - how the gut talks to the brain.
    Korner J; Leibel RL
    N Engl J Med; 2003 Sep; 349(10):926-8. PubMed ID: 12954739
    [No Abstract]   [Full Text] [Related]  

  • 26. The emerging roles of leptin and ghrelin in cardiovascular physiology and pathophysiology.
    Sharma V; McNeill JH
    Curr Vasc Pharmacol; 2005 Apr; 3(2):169-80. PubMed ID: 15853636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension.
    Engeli S; Sharma AM
    Curr Opin Cardiol; 2002 Jul; 17(4):355-9. PubMed ID: 12151869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The YY3-36 peptide, a new therapeutic weapon against obesity?].
    Jégou S; Mounien L; Boutelet I; Vaudry H
    Med Sci (Paris); 2003 May; 19(5):537-9. PubMed ID: 12836385
    [No Abstract]   [Full Text] [Related]  

  • 29. Obesity and insulin resistance in resistant hypertension: implications for the kidney.
    Rao A; Pandya V; Whaley-Connell A
    Adv Chronic Kidney Dis; 2015 May; 22(3):211-7. PubMed ID: 25908470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity hypertension: the emerging role of leptin in renal and cardiovascular dyshomeostasis.
    Kshatriya S; Reams GP; Spear RM; Freeman RH; Dietz JR; Villarreal D
    Curr Opin Nephrol Hypertens; 2010 Jan; 19(1):72-8. PubMed ID: 19851106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of leptin in obesity-related hypertension.
    Haynes WG
    Exp Physiol; 2005 Sep; 90(5):683-8. PubMed ID: 16105937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mechanisms of hypertension in obesity].
    López de Fez CM; Gaztelu MT; Rubio T; Castaño A
    An Sist Sanit Navar; 2004; 27(2):211-9. PubMed ID: 15381953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases.
    Balasubramanian P; Hall D; Subramanian M
    Geroscience; 2019 Feb; 41(1):13-24. PubMed ID: 30519806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity hypertension: role of leptin and sympathetic nervous system.
    Hall JE; Hildebrandt DA; Kuo J
    Am J Hypertens; 2001 Jun; 14(6 Pt 2):103S-115S. PubMed ID: 11411745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Energy homeostasis, obesity and eating disorders: recent advances in endocrinology.
    Gale SM; Castracane VD; Mantzoros CS
    J Nutr; 2004 Feb; 134(2):295-8. PubMed ID: 14747663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin.
    Martin NM; Small CJ; Sajedi A; Patterson M; Ghatei MA; Bloom SR
    Int J Obes Relat Metab Disord; 2004 Jul; 28(7):886-93. PubMed ID: 15148507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertension in obesity.
    Kurukulasuriya LR; Stas S; Lastra G; Manrique C; Sowers JR
    Endocrinol Metab Clin North Am; 2008 Sep; 37(3):647-62, ix. PubMed ID: 18775357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity.
    Mark AL; Correia M; Morgan DA; Shaffer RA; Haynes WG
    Hypertension; 1999 Jan; 33(1 Pt 2):537-41. PubMed ID: 9931161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction between leptin and sympathetic nervous system in hypertension.
    Haynes WG
    Curr Hypertens Rep; 2000 Jun; 2(3):311-8. PubMed ID: 10981165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular and anatomical determinants of central leptin resistance.
    Münzberg H; Myers MG
    Nat Neurosci; 2005 May; 8(5):566-70. PubMed ID: 15856064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.